866-997-4948(US-Canada Toll Free)

Sprycel (Chronic Myeloid Leukemia) - Forecast and Market Analysis to 2022

Published By :

GlobalData

Published Date : May 2013

Category :

Oncology

No. of Pages : 56 Pages


Sprycel (Chronic Myeloid Leukemia) Forecast and Market Analysis to 2022

Summary

GlobalData has released its new PharmaPoint Drug Evaluation report, “Sprycel (Chronic Myeloid Leukemia) Forecast and Market Analysis to 2022”. Chronic myeloid leukemia (CML) is a rare myeloproliferative blood cancer that is characterized by the presence of the BCR-ABL fusion protein. The stage of CML is classified as chronic, accelerated or blast phase, ranging from least to most severe. Multiple BCR-ABL tyrosine kinase inhibitors (TKIs) are approved, and are the standard of care for CML. TKIs have transformed most cases of the disease into a manageable, chronic condition. As a result, patients’ survival rates and the prevalence of CML are increasing, placing a growing burden on global healthcare systems. 

BMS’ Sprycel (dasatinib) is a second-generation BCR-ABL TKI. Sprycel has a slightly different mechanism of action (MOA) than other TKIs used to treat CML, as it also inhibits the SRC family kinases, c-KIT, EPHA2 and PDGFRß. Some KOLs believe that Sprycel is the strongest second-generation TKI, particularly in BP patients, because it inhibits these other kinases in addition to BCR-ABL. Sprycel is designated as an orphan drug by both the FDA and the EMA. It was first approved for adult CML patients with any phase disease who had failed or were intolerant to prior therapy, including Gleevec, in the US and 5EU in 2006, and Japan in 2009. Sprycel received a brand extension to include newly diagnosed adults with CP CML in the US/5EU in 2010 and in Japan in 2011.

Scope


  • Overview of CML, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
  • Detailed information on Sprycel including product description, safety and efficacy profiles as well as a SWOT analysis.
  • Sales forecast for Sprycel for the top seven countries from 2012 to 2022.
  • Sales information covered for the US, France, Germany, Italy, Spain, the UK and Japan

Reasons to buy


  • Understand and capitalize by identifying products that are most likely to ensure a robust return
  • Stay ahead of the competition by understanding the changing competitive landscape for CML
  • Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
  • Make more informed business decisions from insightful and in-depth analysis of Sprycel performance
  • Obtain sales forecast for Sprycel from 2012-2022 in top seven countries (the US, France, Germany, Italy, Spain, the UK and Japan)
Table of Contents

1 Table of Contents
1 Table of Contents 5
1.1 List of Tables 7
1.2 List of Figures 7

2 Introduction 8
2.1 Catalyst 8
2.2 Related Reports 8

3 Disease Overview 10
3.1 Etiology and Pathophysiology 10
3.1.1 Etiology 10
3.1.2 Pathophysiology 11
3.1.3 Clinical Staging 13
3.1.4 Prognosis 14
3.1.5 Quality of Life 15
3.2 Symptoms 16

4 Disease Management 17
4.1 Global Trends 17
4.1.1 Treatment Overview 17
4.1.2 Diagnostic Tests 20
4.1.3 Genetic Testing 21
4.1.4 Monitoring Patient Response to Treatment 23
4.1.5 Future Directions: Discontinuation Therapy 26

5 Competitive Assessment 28
5.1 Overview 28
5.2 Strategic Competitor Assessment 29

6 Product Profile - Sprycel (dasatinib) 32
6.1 Overview 32
6.2 Efficacy 34
6.3 Safety 35
6.4 SWOT Analysis 36
6.5 Forecast 37

7 Appendix 39
7.1 Bibliography 39
7.2 Abbreviations 42
7.3 Methodology 45
7.4 Forecasting Methodology 45
7.4.1 Diagnosed CML patients 45
7.4.2 Drug-treated Patients on X Line of Therapy 46
7.4.3 General Pricing Assumptions 46
7.4.4 Compliance Assumptions for Oral TKIs 48
7.4.5 Individual Drug Assumptions 49
7.4.6 Generic Erosion 49
7.5 Physicians and Specialists Included in this Study 50
7.6 Survey of High Prescribing Physicians 51
7.7 About the Authors 52
7.7.1 Authors 52
7.7.2 Epidemiologists 53
7.7.3 Global Director of Epidemiology and Clinical Trials Analysis 54
7.7.4 Global Head of Healthcare 55
7.8 About GlobalData 56
7.9 Contact Us 56
7.10 Disclaimer 56

List of Table


Table 1: The Staging of CML as Defined by Commonly Used Staging Systems 13
Table 2: Prognostic Scoring Systems for CML 14
Table 3: Common Symptoms of CML by Disease Phase 16
Table 4: Most Commonly Followed Treatment Guidelines for CML 19
Table 5: Most Prescribed First-Line Therapies for CP, AP and BP CML in the Global Markets, 2013 19
Table 6: Suggested Treatments for CML Patients with Selected BCR-ABL Kinase Domain Mutations 22
Table 7: CML Response Types, Criteria, and Corresponding Tests 24
Table 8: Leading Treatments for Chronic Myeloid Leukemia, 2013 31
Table 9: Product Profile Sprycel 33
Table 10: Hematologic and Cytogenetic Reponses to Sprycel in Imatinib Resistant or Intolerant Advanced Phase CML 35
Table 11: Sprycel SWOT Analysis, 2013 36
Table 12: Global Sales Forecasts ($m) for Sprycel in CML, 20122022 38
Table 13: Physicians Surveyed, by Country 51

List of Chart


Figure 1: Translocation of Chromosomes 9 and 22 10
Figure 2: Comparison of Normal and Leukemia Blood Cells 11

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *